Chemotherapy for Retinoblastoma: An Overview

Clinical Ophthalmic Oncology

Volumn , Issue , 2007, Pages 449-453

  Jubran, Rima F ^a   Villablanca, Judith G ^a   Meadows, Anna T ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882879216     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3167-3.50079-6     Document Type: Chapter

References (39)

1. White L Chemotherapy in retinoblastoma: current status and future directions. Am J Pediatr Hematol Oncol 1991, 13:189-201.
2. Kingston JE, Hungerford JL, Madreperla SA, et al. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996, 114:1339-1343.
3. Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996, 114:1330-1338.
4. Murphree AL, Villablanca JG, Deegan WF, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996, 114:1348-1356.
5. Freidman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clinical Oncol 2000, 22:12-17.
6. Jubran RF, Murphree AL, Villablanca JG. 'High dose' CEV and local ophthalmic therapy for group B intraocular retinoblastoma. Proceedings 12th International Symposium on Retinoblastoma, 2005.
7. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002, 133:657-664.
8. Abramson DH, Frank CM, Dunkel IJ A phase I/II study of subconjuctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999, 106:1947-1950.
9. Villablanca JG, Jubran RF, Murphree AL. Phase I study of subtenon carboplatin with systemic high dose carboplatin/etoposide/vincristine for group C, D and E intraocular retinoblastoma. Proceedings 12th International Symposium on Retinoblastoma, 2005.
10. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 2003, 121:1120-1124.
11. Rodriguez-Gallindo C, Wilson MW, Haik BG, et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clinical Oncol 2003, 21:2019-2025.
12. Abramson DH, Beaverson KL, Lee, TC et al. Single agent (carboplatin) chemoreduction for Reese-Ellsworth groups I-III. Proceedings 12th International Symposium on Retinoblastoma, 2005.
13. Chan HSL, Heon E, Budning A et al. Improvement in the cure rate of intraocular retinoblastoma without significantly increasing toxicity with higher dose carboplatin-teniposide in a cyclosporine multidrug reversal regimen. Proceedings 10th International Symposium on Retinoblastoma, 2002.
14. Landsdale P, Berry DH, Holcomb TM, et al. Chemotherapeutic trials in patients with metastatic retinoblastoma. Cancer Chemother Rep 1968, 52:631-634.
15. Pratt CB, Crom DB, Howarth C The use of chemotherapy for extraocular retinoblastoma. Med Pediatr Oncol 1985, 13:330-333.
16. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporine with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 1996, 2:1499-1508.
17. Murphree AL Intraocular retinoblastoma: The case for a new group classification. Ophthalmol Clin North Am 2005, 18:41-53.
18. Blommaert FA, van Dijk-Knijnenburg HC, Dijt FJ, et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 1995, 34:8474-8489.
19. Reed E Cisplatin and analogs. Cancer chemotherapy principles and practice 2001, 447-465. JB Lippincott, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
20. Prommier Y DNA topoisomerase II inhibitors. Cancer therapeutics: experimental and clinical agents 1997, 153. Humana Press, Totowa, NJ. B.A. Teicher (Ed.).
21. Smyth RL, Pfeffer M, Scalzo A, et al. Bioavailability and pharmacokinetics of etoposide. Semin Oncol 1985, 12:48.
22. Pommer YG, Goldwasser F, Strumberg D Topoisomerase II inhibitors: Epipodophyllotoxins, acridines, ellipticines and bisdioxopiperazines. Cancer chemotherapy principles and practice 2001, 538-578. JB Lippincott, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
23. Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992, 326:1745.
24. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999, 17:567.
25. Correia JJ Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol Ther 1991, 52:127.
26. Rowinsky EK, Donehower RC Antimicrotubule agents. Cancer chemotherapy principles and practice 2001, 329-372. JB Lippincott, Philadelphia. B.A. Chabner, D.L. Longo (Eds.).
27. Honavar SG, Singh AD, Shields CL, et al. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 2002, 120:923-931.
28. Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol 2001, 119:41-48.
29. Chantada GL, Dunkel IJ, DeDavila MTG, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy?. Br J Ophthalmol 2004, 88:1069-1073.
30. Donaldson SS, Egbert PR, Newsham I, et al. Retinoblastoma. Principles and practice of pediatric oncology 2002, 825-846. Lippincott-Raven, Philadelphia. 4th edn. P.A. Pizzo, D.G. Poplack (Eds.).
31. Dunkel IJ, Aledo A, Kerman N, et al. Successful treatment of metastatic retinoblastoma. Cancer 2000, 89:2117-2121.
32. Chantada G, Fadino A, Casak, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol 2003, 40:158-161.
33. Antoneli CBG, Steinhorst F, Ribeiro KCB, et al. Extraocular retinoblastoma: A 13 year experience. Cancer 2003, 98:1292-1298.
34. Namouni F, Doz F, Tanguy ML, et al. High dose chemotherapy with carboplatin, etoposide, and cyclophosphamide followed by haematopoietic stem cell rescue in patients with high risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 1997, 33:2368-2375.
35. Jubran RF, Erdreich-Epstein A, Butturini A, et al. Approaches to treatment of extraocular retinoblastoma. Childrens Hospital Los Angeles experience. J Pediatr Hematol Oncol 2004, 26:31-34.
36. Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 2005, 35:763-766.
37. DePotter P, Shields CL, Shields JA, et al. Clinical variations of trilateral retinoblastoma. J Pediatric Ophthalmol Strabismus 1994, 31:26-31.
38. Amouku WMK, Willshaw HE, Parkes SE, et al. Trilateral retinoblastoma. A report of five patients. Cancer 1996, 78:858-863.
39. Dunkel IJ, Jubran R, Chan HSL et al. Intensive chemotherapy for central nervous system (CNS) retinoblastoma. Proceedings 12th International Symposium on Retinoblastoma, 2005.